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ABSTRACT
Gram-positive infections, both community- and hospital-acquired, have a huge impact on healthcare.
The incidence of Staphylococcus aureus bacteraemia is on the increase, probably due to the rising numbers
of patients with risk-factors for these infections. Antibiotic resistance has seriously compromised
treatment options for Gram-positive infections, most notably those caused by staphylococci and
enterococci. Until recently, methicillin-resistant S. aureus (MRSA) was observed mainly in healthcare-
associated infections, but a significant rise in community-associated MRSA is being reported, especially
in the USA. In the last decade, vancomycin-resistant enterococci (VRE) have become the second most
important group of pathogens among intensive care patients in US hospitals, and VRE outbreaks are
currently emerging in European hospitals. The changing patterns of both MRSA and VRE are associated
with a changing molecular epidemiology, in which sub-populations with obvious enhanced epidemic
potential are rapidly becoming more prominent. These recent epidemiological observations suggest an
increase in difficult-to-treat Gram-positive infections in European hospitals in the coming years, and
underscore the need for new treatment options. Daptomycin, the first cyclic lipopeptide, is a novel
antibiotic with potent in-vitro activity against Gram-positive organisms, including MRSA and VRE. It
has been approved for the treatment of complicated skin and soft tissue infections caused by Gram-
positive bacteria, and registration for treatment of infective endocarditis and bacteraemia is anticipated.
The novel mode of action, rapid in-vitro bactericidal activity against growing and stationary-phase
bacteria, once-daily dosing regimen, and no requirement for drug monitoring, could all make
daptomycin an attractive option for the treatment of Gram-positive infections.
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INTRODUCTION
Infections caused by Gram-positive pathogens
represent an increasing healthcare burden. The
emergence of resistance to existing antibiotics
among Gram-positive bacteria has compromised
treatment options for infections caused by these
pathogens. The rate of antibiotic resistance has
increased alarmingly over the last decade in the
USA and Europe, most notably among staphylo-
cocci and enterococci. In addition, the epidemiol-
ogy of these infections is rapidly evolving. As a
result, increased rates of difficult-to-treat infec-
tions are anticipated. An urgent need exists for
new antibiotics to treat infections caused by
Gram-positive bacteria. This article will discuss
the changing epidemiology of infections caused
by Staphylococcus aureus and enterococci, and the
emergence of daptomycin as a treatment option
for infections caused by Gram-positive bacteria.
STAPHYLOCOCCUS AUREUS
INFECTIONS
The incidence of community-associated and
nosocomial S. aureus bacteraemia (SAB) has
increased over several decades [1–3]. This may
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be due to a growing patient population at risk as a
result of the increased prevalence of chronic
disease, the improved survival of patients with
severe chronic underlying diseases, and the
increased use of intravascular devices in hospital
and non-hospital settings [1–3]. The overall
burden of S. aureus infections is substantial, with
estimated total hospital-associated costs per
patient infected of about US$50 000, as compared
with US$15 000 for patients without S. aureus
infection [4].
Most S. aureus infections occur in colonised
persons, with the nares being the predominant
colonisation site. In longitudinal studies, nasal
carriage is persistent in about 20% of people, and
intermittent in another 30% [5,6]. Nosocomial
SAB is most frequently (80% of cases) caused by
S. aureus strains already colonising patients on
entry to hospital [7,8]. As compared to non-
carriers, surgical and non-surgical patients carry-
ing S. aureus have an approximately four-fold
increased risk of developing nosocomial SAB
[7,9]. Interestingly, though, the mortality associ-
ated with SAB seems to be lower in long-term
carriers [7], and this cannot be explained by the
occurrence of specific S. aureus clones infecting
non-carriers [10]. The overall hospital mortality
rate among adult patients suffering from SAB has
remained consistent during the last decades, with
estimates ranging from 23% to 46% [7,11,12].
Significant risk-factors for mortality are a respir-
atory source of SAB or unknown primary infec-
tion, shock, older age, male gender and severity of
underlying disease [13–15].
HEALTHCARE-ASSOCIATED
METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS
INFECTIONS
Healthcare-associated methicillin-resistant S.
aureus (HA-MRSA) infections are usually defined
as those developing in patients hospitalised for
48 h or longer, in patients receiving ambulatory
intravenous therapy, or in patients who recently
attended a hospital, haemodialysis clinic, nursing
home or long-term care facility [16,17]. Some
studies have suggested that HA-MRSA infections
add to the number of infections caused by
methicillin-susceptible S. aureus (MSSA), thereby
enhancing the overall burden of hospital infec-
tions caused by this species [18,19].
MRSA represents the most important antibiotic
resistance problem among healthcare-associated
infections worldwide. The overall prevalence of
MRSA among nosocomial SABs increased from
16% to 24% in Europe between 1999 and 2004
[20], and from 45% to 59.5% in the USA between
1998 and 2003 [21]. MRSA prevalence is currently
as high as 50% in countries around the Mediter-
ranean Sea, southeastern Europe and the United
Kingdom (Fig. 1) [20]. Even in countries with low
endemicity of MRSA, prevalence rates seem to be
on the increase. It is generally believed that MRSA
infections (especially bacteraemia) are, as com-
pared to MSSA infections, associated with higher
mortality [22]. However, these figures may have
been overestimated due to confounding factors
such as severity of illness (length of hospital stay
before onset of bacteraemia) and administration
of initially inappropriate antibiotic therapy.
MRSA strains harbour the mecA gene, carried
on the mobile staphylococcal cassette chromo-
some mec (SCCmec) and integrated into the
S. aureus chromosome. Five types of SCCmec have
been identified, with types I–III being most
prevalent among healthcare-associated MRSA
isolates [23]. Most hospital epidemic MRSA
Fig. 1. The prevalence of methicillin-resistant Staphylo-
coccus aureus across Europe in 2004 [20]. Reproduced with
permission from the European Antimicrobial Resistance
Surveillance System.
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(EMRSA) isolates belong to five globally dis-
persed clonal complexes (CC). For example,
CC30, containing the UK EMRSA-16 clone, and
CC22, containing EMRSA-15, are responsible for
95.6% of MRSA bacteraemia cases in the UK
[24,25].
In addition to the treatment problems caused
by MRSA, staphylococcal isolates with reduced
susceptibility to vancomycin [vancomycin-inter-
mediate S. aureus (VISA)] have emerged. About
100 VISA isolates have been reported in Europe,
Asia and the USA since 1996 [26]. Moreover, four
vancomycin-resistant S. aureus (VRSA) strains
have been reported in the USA since 2002 [26–
29]. In at least one of these strains, cross-species
transfer of vancomycin resistance genes from
enterococci to MRSA was demonstrated [30].
Patients with VISA or VRSA infection had usually
been treated with multiple courses of antibiotic
therapy, predisposing them to complicated,
multidrug-resistant infections [26].
COMMUNITY-ASSOCIATED
METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS
INFECTIONS
Community-associated MRSA (CA-MRSA) is
defined epidemiologically as an MRSA strain
isolated within 48 h of hospital admission from
patients who: have not been administered intra-
venous antibiotics within the last 30 days; have
not received haemodialysis; have not been hospi-
talised in the preceding year (with different
durations being used); and do not reside in a
long-term care facility [17]. Probably more appro-
priate is the molecular epidemiological definition
based on SCCmec typing, presence of the Panton–
Valentine leukocidin virulence factor, and MRSA
genotyping. CA-MRSA strains typically contain
SCCmec type IV or V, frequently harbour Panton–
Valentine leukocidin genes, and are phylogenet-
ically unrelated to HA-MRSA [31,32].
The initial reported clusters of CA-MRSA
appeared coincidentally at multiple sites in the
world, suggesting horizontal spread of the
SCCmec gene complex to susceptible S. aureus
strains followed by clonal dissemination. The fact
that the type IV SCCmec gene is the smallest of the
known SCCmec elements might favour horizontal
transmission. A recent study suggests the
re-emergence of a highly virulent pandemic peni-
cillin-resistant S. aureus strain known as phage
type 80 ⁄ 81, which was first identified in the 1950s.
This strain disappeared with the introduction of
penicillinase-resistant penicillins (such as methi-
cillin) in the 1960s, but now appears to be
identical to ST30, one of the predominant geno-
types of CA-MRSA with Panton–Valentine leuk-
ocidin and SCCmec type IV [33].
In the USA, the epidemiology of CA-MRSA has
all the characteristics of a nationwide monoclonal
outbreak. The first sign of this outbreak was a
series of fatal cases of CA-MRSA due to clone
USA400, reported in 1999 [31]. This USA400
clone has been replaced by the so-called USA300
clone [34]. Across most regions of the USA,
proportions of MRSA are similar for S. aureus
infections contracted within and outside hospital
settings [35]. Nevertheless, the carriage rate of
MRSA among non-institutionalised persons in the
USA is 0.84%, as compared to 31.6% for MSSA.
As several risk-factors were clearly healthcare-
related and SCCmec and genotypes were not
determined, the majority of these persons may
well be colonised with HA-MRSA [36]. Cross-
sectional prevalence studies among 3525 Portu-
guese persons without prior healthcare contact
and 10 000 Dutch persons admitted for non-
surgical reasons—both studies performed around
2000—revealed MRSA colonisation prevalences of
0.20% and 0.03%, respectively [37,38]. The epi-
demiological difference in CA-MRSA between
Europe and the USA is, as yet, unexplained.
Differences in outpatient antibiotic use or popu-
lation structures might be contributing factors,
but, to the best of our knowledge, this has not
been studied.
ENTEROCOCCAL INFECTIONS
Enterococci are intrinsically resistant to a broad
range of antibiotics, including cephalosporins,
pencillinase-resistant penicillins, sulphonamides
and low concentrations of aminoglycosides
[39,40]. Low-level resistance to b-lactam antibiot-
ics in enterococci is attributable to the production
of a low-affinity penicillin-binding protein (PBP),
PBP5; increased resistance results from either the
production of b-lactamase or alterations in the
expression or structure of PBP5 [41]. In addition
to these intrinsic resistance mechanisms, entero-
cocci acquire resistance traits through transfer of
plasmids and transposons, chromosomal
24 Clinical Microbiology and Infection, Volume 12 Supplement 8, 2006
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exchange, or mutation [42]. Vancomycin resist-
ance is conferred by one of two functionally
similar operons, VanA or VanB. Mostly found
among Enterococcus faecalis and Enterococcus fae-
cium, VanA and VanB genes may be transferred
by plasmids or conjugative transposons to other
enterococci, and also to MRSA. Vancomycin-
resistant enterococci (VRE) were first encountered
in France and the UK in 1986, but the most
dramatic increase in nosocomial prevalence has
been reported in the USA. From being nearly
absent in 1990, by 2000 VRE accounted for
approximately 30% of enterococcal bloodstream
infections among patients in intensive care units
(Fig. 2) [21]. In the same period, VRE infections
were only sporadically encountered in Europe.
The epidemiology of VRE differs markedly
between the USA and Europe. The rapid increase
in nosocomial prevalence in the USA is presum-
ably due to the widespread use of vancomycin,
while hardly any VRE have been detected in non-
hospitalised persons. In Europe, colonisation rates
of VRE appear to be high in the community
(among animals and healthy humans), while
nosocomial outbreaks and infections remain
sparse; in a 1997 report, 12% of non-hospitalised
persons and 34% of farm animals in The Neth-
erlands were colonised with VRE [43]. This
population reservoir in Europe has been attrib-
uted to the widespread use over many years of
another glycopeptide, avoparcin, as a growth
promoter in animal husbandry. For example, in
1994, the amount of avoparcin used for livestock
in Denmark alone exceeded the total clinical use
of vancomycin in the USA and Europe [44].
Avoparcin was banned in 1997 because of its
presumed role in creating and selecting VRE, and
since then community prevalence levels of VRE
have decreased [45]. Proportions of VRE among
enterococcal bloodstream infections in Europe are
still low, but increased from 3.3% in 2003 to 7.8%
in 2004. The largest increases were reported from
Germany, France and Ireland [20].
Recent molecular epidemiological studies of
E. faecium have identified a specific clonal com-
plex (CC17) associated with hospital outbreaks
and clinical infections [46]. CC17 isolates have
now been identified in hospitals in five conti-
nents, but never among European animals and
people. CC17 strains are resistant to ampicillin
and quinolones. Vancomycin resistance is not
associated with CC17, but is dispersed through-
out the E. faecium population, confirming the
importance of horizontal gene transfer for the
development of this resistance.
DAPTOMYCIN
Daptomycin is a cyclic lipopeptide that exhibits
rapid, dose-related in-vitro bactericidal activity
against a broad range of Gram-positive patho-
gens, including MSSA, MRSA and VRE (Fig. 3)
[47–50]. It has a unique mechanism of action that
involves Ca2+-dependent insertion of a lipophilic
tail into the bacterial cytoplasmic membrane,
triggering a release of intracellular K+. The result-
ing decrease in membrane potential causes cell
death by inhibition of DNA, RNA and protein
synthesis [51]. As a result of this mechanism of
action, daptomycin is active against growing and
stationary-phase bacteria, and might therefore be
a promising drug for infections associated with
biofilm formation [52].
Fig. 2. The increase in vancomycin-resistant enterococci in
the USA [21].
Fig. 3. Dose-related activity of daptomycin against meth-
icillin-resistant Staphylococcus aureus [50]. D1 through D6,
daptomycin at dose regimens simulating 1 to 6 mg/kg
every 24 hours. Reproduced with permission from the
American Society for Microbiology. GC, growth control; D,
daptomycin.
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Two phase III randomised, controlled trials
have compared daptomycin with penicillinase-
resistant penicillins or vancomycin for the treat-
ment of complicated skin and soft tissue infec-
tions (cSSTIs) [53]. These studies, involving more
than 1000 patients, showed that daptomycin was
not inferior to the comparator antibiotics. Clinical
success rates in the combined intention-to-treat
population were 71.5% and 71.1% following
daptomycin and comparator treatment, respect-
ively (95% CI )4.0–5.6) [53]. The findings were
robust and consistent across predefined patient
populations, different infecting Gram-positive
organisms and different types of infection. Dap-
tomycin is now approved in Europe for the
treatment of cSSTIs caused by Gram-positive
pathogens [54]. Approval for treating SABs, with
or without endocarditis, is currently under con-
sideration. Daptomycin did not meet statistical
non-inferiority criteria in a clinical trial for severe
community-acquired pneumonia; in-vitro studies
showed an interaction between daptomycin and
lung surfactant, resulting in inhibition of antibac-
terial activity [55].
Data from clinical trials indicate that daptomy-
cin is well-tolerated at doses of 4 and 6 mg ⁄ kg
administered intravenously once-daily, with a
safety profile similar to that of comparators
[53,56]. Adverse events, such as creatine phos-
phokinase elevation, were mostly mild and
resolved spontaneously after drug interruption
[53,56]. In dogs, adverse skeletal-muscle effects
were related to dosing frequency rather than drug
concentrations [57]. In agreement with this, clin-
ical trials have shown that once-daily dosing
results in less adverse skeletal-muscle effects
compared with twice-daily dosing, while being
equally effective [58,59].
The recommended dose of daptomycin for the
treatment of cSSTIs is 4 mg ⁄ kg once-daily for
7–14 days or until the infection is resolved [60]. As
daptomycin is primarily excreted in urine, dosage
adjustment is necessary in patients with severe
renal insufficiency (creatinine clearance
(Clcr) <30 mL ⁄min), and renal function should be
monitored in patients with Clcr <80 mL ⁄min. For
patients with Clcr <30 mL ⁄min (including patients
receiving haemodialysis or continuous ambula-
tory peritoneal dialysis), dose intervals should be
prolonged to 48 h [49,54,56,58,59,61]. In a recent
phase III clinical trial, a higher dose of daptomycin
(6 mg ⁄kg once-daily) was tested and shown to be
effective for the treatment of SAB and known or
suspected endocarditis [62].
In vitro, daptomycin appears to have a low
resistance potential, but resistance in MRSA has
been reported in patients receiving prolonged
daptomycin monotherapy [63–65]. In these cases,
cell-wall thickening seems to be the most likely
resistance mechanism [66]. Another study has
shown many soil-derived bacterial isolates to be
resistant to daptomycin [67], which is unsurpris-
ing given that daptomycin is a fermentation
product of Streptomyces roseosporus. Therefore,
resistance genes are naturally present and, as for
any other antibiotics, bacterial resistance to dap-
tomycin will always be a possibility.
CONCLUSION
The epidemiological and clinical spectrum of
Gram-positive infections is rapidly changing
worldwide, with the emergence of specific clonal
complexes of CA-MRSA and E. faecium being the
most dramatic examples. In addition to these
molecular epidemiological changes, patient pop-
ulation characteristics continue to evolve, thereby
increasing the risk of nosocomial staphylococcal
and enterococcal infections. Hence, increased
infection rates of difficult-to-treat Gram-positive
pathogens should be expected in the coming
years. In this respect, daptomycin may offer a
valuable and convenient addition to the available
antimicrobial armamentarium. In Europe, dapto-
mycin is approved for the treatment of cSSTIs. It
has recently been approved by the US FDA for
the treatment of SAB and right-sided endocardi-
tis, and an application for these indications is
currently underway in Europe. Future studies
should provide more data on the activity of
daptomycin in other indications, as well as on its
safety profile and the potential for development
of resistance.
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